Clinical Trials
15 trialsNCT05316155 2026-06-05
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT05710848 2026-05-27
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
SURGE Therapeutics
Phase 1/2 Recruiting
NCT06637423 2026-05-01
TroFuse-027
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04752722 2026-04-30
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
enGene, Inc.
Phase 1/2 Recruiting
NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT07505615 2026-04-01
VG-INFUSE Tria
Fudan University
Phase 1/2 Completed
NCT02138734 2026-03-31
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
ImmunityBio, Inc.
Phase 1/2 Active not recruiting
NCT06704191 2026-03-30
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Phase 1/2 Recruiting
NCT06800963 2026-03-27
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
ImmunityBio, Inc.
Phase 1/2 Recruiting
NCT07445308 2026-03-03
The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1/2 Not yet recruiting
NCT05544552 2026-01-12
SURF301
Tyra Biosciences, Inc
Phase 1/2 Active not recruiting
NCT07122414 2025-08-14
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2 Recruiting
NCT07064863 2025-07-17
BCG-TIME
Queen's University
Phase 1/2 Not yet recruiting
NCT03081858 2025-06-27
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Phase 1/2 Completed
NCT04179162 2025-06-13
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting